CA2901162C - Purification of rapamycin derivatives - Google Patents

Purification of rapamycin derivatives Download PDF

Info

Publication number
CA2901162C
CA2901162C CA2901162A CA2901162A CA2901162C CA 2901162 C CA2901162 C CA 2901162C CA 2901162 A CA2901162 A CA 2901162A CA 2901162 A CA2901162 A CA 2901162A CA 2901162 C CA2901162 C CA 2901162C
Authority
CA
Canada
Prior art keywords
purification
rapamycin derivatives
biolimus
formula
purified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2901162A
Other languages
English (en)
French (fr)
Other versions
CA2901162A1 (en
Inventor
Margaret W. KAYO
Richard S. Fornicola
Ivan KOVACIK
Leelakrishna Kondaveti
Aniruddh SINGH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biosensors International Group Ltd
Original Assignee
Biosensors International Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosensors International Group Ltd filed Critical Biosensors International Group Ltd
Publication of CA2901162A1 publication Critical patent/CA2901162A1/en
Application granted granted Critical
Publication of CA2901162C publication Critical patent/CA2901162C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2901162A 2013-03-15 2014-03-17 Purification of rapamycin derivatives Active CA2901162C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361799857P 2013-03-15 2013-03-15
US61/799,857 2013-03-15
PCT/US2014/030602 WO2014145780A1 (en) 2013-03-15 2014-03-17 Purification of rapamycin derivatives

Publications (2)

Publication Number Publication Date
CA2901162A1 CA2901162A1 (en) 2014-09-18
CA2901162C true CA2901162C (en) 2021-06-01

Family

ID=51538094

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2901162A Active CA2901162C (en) 2013-03-15 2014-03-17 Purification of rapamycin derivatives

Country Status (8)

Country Link
US (5) US9598439B2 (enExample)
EP (1) EP2972258B1 (enExample)
JP (4) JP2016519086A (enExample)
CN (2) CN108864149B (enExample)
CA (1) CA2901162C (enExample)
ES (1) ES2897473T3 (enExample)
SG (3) SG11201507406YA (enExample)
WO (1) WO2014145780A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2934401C (en) 2009-11-02 2017-01-10 Pulse Therapeutics, Inc. Magnetomotive stator system and methods for wireless control of magnetic rotors
CN108864149B (zh) 2013-03-15 2022-04-05 生物传感器国际集团有限公司 雷帕霉素衍生物的纯化
CN109851626B (zh) * 2019-01-08 2021-11-02 扬子江药业集团四川海蓉药业有限公司 一种替西罗莫司的分离纯化方法
CN116102576B (zh) * 2021-11-09 2025-08-29 上海博畅医疗科技有限公司 一种优美莫司晶体的制造方法及其应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9713730D0 (en) * 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
US20060198867A1 (en) * 1997-09-25 2006-09-07 Abbott Laboratories, Inc. Compositions and methods of administering rapamycin analogs using medical devices for long-term efficacy
US7452692B2 (en) 2002-02-13 2008-11-18 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Method for extracting a macrolide from biomatter
KR20050114262A (ko) * 2003-03-31 2005-12-05 테바 기오기스제르갸르 레스즈베니타르사사그 마크로라이드의 결정화 및 정제
US7220755B2 (en) * 2003-11-12 2007-05-22 Biosensors International Group, Ltd. 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
CA2548297C (en) * 2003-12-05 2011-06-14 Biocon Limited Process for the purification of macrolides
JP4716280B2 (ja) * 2004-03-01 2011-07-06 テルモ株式会社 Ｏ−アルキル化ラパマイシン誘導体の製造法
KR20070015544A (ko) * 2004-04-14 2007-02-05 와이어쓰 라파마이신 42-에스테르 유도체의 위치특이성 합성
WO2006060615A1 (en) 2004-12-01 2006-06-08 Teva Gyógyszergyár Zàrtköruen Muködo Rèszvènytàrsasàg Non-hygroscopic and powdery amorphous pimecrolimus
AU2006218918A1 (en) * 2005-03-02 2006-09-08 Wyeth Purification of rapamycin
US20060222627A1 (en) * 2005-03-30 2006-10-05 Andrew Carter Optimizing pharmacodynamics of therapeutic agents for treating vascular tissue
JP2009518648A (ja) * 2005-12-07 2009-05-07 ワイス 結晶性ラパマイシンを調製するための方法およびを示差走査熱量測定使用してラパマイシン化合物の結晶化度を測定するための方法
US7700614B2 (en) * 2005-12-14 2010-04-20 Abbott Laboratories One pot synthesis of tetrazole derivatives of rapamycin
GB0601406D0 (en) * 2006-01-24 2006-03-08 Novartis Ag Organic Compounds
CA2644156A1 (en) 2006-03-07 2007-09-13 Wyeth Process for preparing water-soluble polyethylene glycol conjugates of macrolide immunosuppressants
US7820812B2 (en) * 2006-07-25 2010-10-26 Abbott Laboratories Methods of manufacturing crystalline forms of rapamycin analogs
US7812032B2 (en) * 2006-07-25 2010-10-12 Abbott Laboratories Crystalline forms of rapamycin analogs
BRPI0621967A2 (pt) * 2006-11-10 2011-12-27 Biocon Ltd forma pura de rapamicina e um processo para recuperaÇço e purificaÇço da mesma
WO2008065887A1 (en) * 2006-11-27 2008-06-05 Terumo Kabushiki Kaisha Process for producing o-alkylated rapamycin derivative, and o-alkylated rapamycin derivative
US20080287675A1 (en) * 2007-05-18 2008-11-20 Abbott Laboratories Cascade system
CN101077334A (zh) * 2007-06-29 2007-11-28 济南康泉医药科技有限公司 含酪氨酸激酶抑制剂的抗癌组合物
TW200948361A (en) 2008-05-26 2009-12-01 Chunghwa Chemical Synthesis & Biotech Co Ltd Method for synthesizing Biolimus A9 and the like and method for improving stability of the same
US20100055145A1 (en) * 2008-08-29 2010-03-04 Biosensors International Group Stent coatings for reducing late stent thrombosis
EP2421571A2 (en) 2009-04-24 2012-02-29 Boston Scientific Scimed, Inc. Use of drug polymorphs to achieve controlled drug delivery from a coated medical device
CN102464669B (zh) * 2010-11-17 2014-04-16 浙江海正药业股份有限公司 无定形依维莫司及其制备方法
US8669360B2 (en) * 2011-08-05 2014-03-11 Boston Scientific Scimed, Inc. Methods of converting amorphous drug substance into crystalline form
WO2013028208A1 (en) 2011-08-25 2013-02-28 Boston Scientific Scimed, Inc. Medical device with crystalline drug coating
CN102786534A (zh) * 2012-05-25 2012-11-21 上海现代制药股份有限公司 一种依维莫司的制备方法
CN108864149B (zh) 2013-03-15 2022-04-05 生物传感器国际集团有限公司 雷帕霉素衍生物的纯化

Also Published As

Publication number Publication date
US20200270272A1 (en) 2020-08-27
EP2972258A4 (en) 2016-12-21
SG10202112135VA (en) 2021-12-30
JP2021121601A (ja) 2021-08-26
WO2014145780A1 (en) 2014-09-18
CN108864149B (zh) 2022-04-05
JP2023164476A (ja) 2023-11-10
JP2019089848A (ja) 2019-06-13
US20160002262A1 (en) 2016-01-07
ES2897473T3 (es) 2022-03-01
US10597406B2 (en) 2020-03-24
CN108864149A (zh) 2018-11-23
WO2014145780A4 (en) 2014-11-20
US9598439B2 (en) 2017-03-21
SG11201507406YA (en) 2015-10-29
US11046711B2 (en) 2021-06-29
US10202402B2 (en) 2019-02-12
CA2901162A1 (en) 2014-09-18
CN105102967B (zh) 2018-10-12
JP2016519086A (ja) 2016-06-30
EP2972258A1 (en) 2016-01-20
HK1218959A1 (zh) 2017-03-17
US11780850B2 (en) 2023-10-10
EP2972258B1 (en) 2021-08-04
US20190256527A1 (en) 2019-08-22
CN105102967A (zh) 2015-11-25
US20220024947A1 (en) 2022-01-27
US20170334928A1 (en) 2017-11-23
SG10201707632PA (en) 2017-11-29

Similar Documents

Publication Publication Date Title
PH12015500263A1 (en) New bicyclic derivatives
PH12015501934B1 (en) New octahydro - pyrrolo [3,4-c] - pyrrole derivatives and analogs thereof as autotaxin inhibitors
PH12014500883A1 (en) Uracil derivatives as axl and c-met kinase inhibitors
PH12015502031B1 (en) Tetrahydropyrrolothiazine compounds
PH12014501179B1 (en) New bicyclic dihydroisoquinoline-1-one derivatives
WO2014100764A3 (en) Methods of inhibiting prmt5
MY199066A (en) Processes for producing diazabicyclooctane compounds
WO2016011390A8 (en) Irak4 inhibiting agents
WO2014144545A3 (en) Substituted benzoxazoles and methods of use thereof
EP4643945A8 (en) Neuroactive steroids and methods of use thereof
MY182986A (en) Pyrrolo [1,2,f] [1,2,4] triazines useful for treating respiratory syncitial virus infections
MX2015012629A (es) Compuestos de imidazo piridina.
WO2014031872A3 (en) Small molecule inhibitors for treating parasitic infections
ES2657549T3 (es) Piridopirazinas sustituidas como nuevos inhibidores de SYK
JO3318B1 (ar) مثبطات bace
WO2013120940A3 (en) Nematicidal cis (hetero)arylcyclopropylcarboxamide derivatives
MX353190B (es) Derivados de isoquinolina y naftiridina.
AU2014230812A8 (en) Process for making benzoxazepin compounds
MX2016002718A (es) Derivados de ceto-imidazopiridina como moduladores del receptor huerfano relacionado con receptor retinoide (porc).
WO2013152065A3 (en) 1,8-naphthyridin-2(1h)-one derivatives as cytomegalovirus inhibitors
JOP20200030A1 (ar) مركب خماسي الحلقة
WO2013178322A8 (en) Spiro tetrahydro - benzothiophen derivatives useful for the treatment neurodegenerative diseases
MX2016007985A (es) Compuestos de fluorofenilpirazol.
PH12017501404A1 (en) Diaza-benzofluoranthrene compounds
WO2014087208A3 (en) A process of preparing alcaftadine

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190306

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250307

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250307

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250307

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260309

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260309